Rhythm Metabolic
Boston · Founded 2013
About Rhythm Metabolic
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Company Facts
- Founded: 2013
- Legal name: RHYTHM PHARMACEUTICALS, INC.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $40.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2015)
- Website: rhythmtx.com
Social Profiles
Canonical: https://fsome.com/organization/rhythm-metabolic-8443831 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.